Global Ischemic Heart Disease (IHD) Drugs Market to Grow at 3.9% During 2024-2032, Catalyzed by Rising Prevalence of Cardiovascular Diseases

January 07, 2020 | Healthcare

According to the latest report by IMARC Group, titled “Ischemic Heart Disease (IHD) Drugs Market Report by Disease Class (Angina Pectoris, Myocardial Infarction), Drug Class (Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, ACE Inhibitors, ARBs, Vasodilators, and Antithrombotic Agents), and Region 2024-2032”, the global Ischemic Heart Disease (IHD) drugs market reached a value of US$ 6.3 Billion in 2023. Ischemic heart disease, also known as coronary heart (CHD) or coronary artery disease, refers to a heart problem in which the blood flow to the heart is restricted or reduced. This is caused by clogged arteries that supply less blood and oxygen to the heart muscles, eventually leading to a cardiac attack. The diverse pharmacological actions of various IHD drugs, such as calcium channel blockers, inhibit the influx of calcium ions into the myocardium and vascular smooth muscle tissues. The relaxation of the coronary artery due to calcium channel blocker therapy improves coronary blood flow, thereby increasing myocardial oxygen supply. The anti-ischemic effects of these drugs are often notable, especially the newer agents like amlodipine.

Global IHD Drugs Market Trends:

In recent years, the increasing prevalence of heart diseases, along with the growing population of older adults who are more prone to heart ailments, has led to the rising demand for IHD drugs. Moreover, IHD drugs are incorporated in various cardiological treatment procedures, such as angioplasty, atherectomy and balloon angioplasty, for preventing relapse and ensuring healthy recovery, which has led to a consistent requirement for these drugs. Besides this, the high alcohol consumption, excessive smoking, reduced blood pressure control and lower physical activity are the factors that have increased the mortality rate from cardiovascular disease, which in turn is leading to a rise in the demand for IHD drugs across the globe. Moreover, several pharmaceutical companies are investing in the development of more advanced IHD drugs. Looking forward, the market is projected to expand at a CAGR of 3.9% during 2024-2032.

Market Summary:

Based on the disease class, the market has been bifurcated into angina pectoris and myocardial infarction.
On the basis of the drug class, the market has been segregated into anti-dyslipidemic drugs, calcium channel blockers, beta-blockers, Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers (ARBs), vasodilators and antithrombotic agents.
Region-wise, the market has been divided into North America, Asia Pacific, Europe, Middle East and Africa, and Latin America.
The competitive landscape of the market has also been examined, with some of the key players being Bayer AG, Eli Lilly and Company, Novartis International AG, Pfizer, Inc., Sanofi S.A., Actelion Pharmaceuticals Ltd., Baxter International Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Amgen Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co., and Eisai Co., Ltd.

Report Scope:

Report Features	Details
Base Year of the Analysis	2023
Historical Period	2018-2023
Forecast Period	2024-2032
Units	US$ Billion
Segment Coverage	Disease Class, Drug Class, Region
Region Covered	Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Companies Covered	Bayer AG, Eli Lilly and Company, Novartis International AG, Pfizer, Inc., Sanofi S.A., Actelion Pharmaceuticals Ltd., Baxter International Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Amgen Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co., and Eisai Co., Ltd.
Customization Scope	10% Free Customization
Report Price and Purchase Option	Single User License: US$ 3899 Five User License: US$ 4899 Corporate License: US$ 5899
Post-Sale Analyst Support	10-12 Weeks
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
Email: sales@imarcgroup.com
Phone No: (D) +91 120 433 0800 | www.imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163

Need more help?

Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.

Global Ischemic Heart Disease (IHD) Drugs Market to Grow at 3.9% During 2024-2032, Catalyzed by Rising Prevalence of Cardiovascular Diseases

Purchase options

Single User License ~~$3899~~ $2999
Five User License ~~$4899~~ $3999
Corporate User License ~~$5899~~ $4999

Inquire Before Buying

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Speak to an Analyst

Request Brochure

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.